These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32661830)

  • 1. Evaluation of [
    Tsai WK; Zettlitz KA; Dahlbom M; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Oct; 22(5):1380-1391. PubMed ID: 32661830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
    Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody.
    Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM
    J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
    Tsai WK; Zettlitz KA; Tavaré R; Kobayashi N; Reiter RE; Wu AM
    Theranostics; 2018; 8(21):5903-5914. PubMed ID: 30613270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.
    Knowles SM; Tavaré R; Zettlitz KA; Rochefort MM; Salazar FB; Jiang ZK; Reiter RE; Wu AM
    Clin Cancer Res; 2014 Dec; 20(24):6367-78. PubMed ID: 25326233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.
    Lepin EJ; Leyton JV; Zhou Y; Olafsen T; Salazar FB; McCabe KE; Hahm S; Marks JD; Reiter RE; Wu AM
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1529-38. PubMed ID: 20354850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Characterization of the
    Striese F; Neuber C; Gräßel S; Arndt C; Ullrich M; Steinbach J; Pietzsch J; Bergmann R; Pietzsch HJ; Sihver W; Frenz M; Feldmann A; Bachmann MP
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting angiogenesis for radioimmunotherapy with a
    Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas.
    Bhattacharyya S; Kurdziel K; Wei L; Riffle L; Kaur G; Hill GC; Jacobs PM; Tatum JL; Doroshow JH; Kalen JD
    Nucl Med Biol; 2013 May; 40(4):451-7. PubMed ID: 23454247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
    Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
    Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
    Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of the theranostic potential of
    Wu Y; Li T; Zhang X; Jing H; Li F; Huo L
    EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.
    Leyton JV; Olafsen T; Lepin EJ; Hahm S; Bauer KB; Reiter RE; Wu AM
    Clin Cancer Res; 2008 Nov; 14(22):7488-96. PubMed ID: 19010866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.
    Bäck TA; Jennbacken K; Hagberg Thulin M; Lindegren S; Jensen H; Olafsen T; Yazaki PJ; Palm S; Albertsson P; Damber JE; Wu AM; Welén K
    EJNMMI Res; 2020 Feb; 10(1):10. PubMed ID: 32048062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate
    Maaland AF; Heyerdahl H; O'Shea A; Eiriksdottir B; Pascal V; Andersen JT; Kolstad A; Dahle J
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2311-2321. PubMed ID: 31309259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models.
    Zhang M; Kobayashi N; Zettlitz KA; Kono EA; Yamashiro JM; Tsai WK; Jiang ZK; Tran CP; Wang C; Guan J; Wu AM; Reiter RE
    Clin Cancer Res; 2019 Jan; 25(1):188-200. PubMed ID: 30301826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.